source
- Novartis shares tumble as three late-stage drug candidates fail trialsNovartis' stock fell more than 13% this week after news that three of its late-stage programs did not meet expectations, pulling down other pharma stocks in the market. The antibody‑oligonucleotid…
- FDA grants de novo clearance to Powerful Medical’s AI tool for detecting severe heart attacks on EKGsThe U.S. Food and Drug Administration issued a de novo classification for Powerful Medical’s AI algorithm that analyzes electrocardiograms to identify severe heart attacks. This clearance allows th…